Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408542 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL29879680 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL2569233 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL2569312 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL7408543 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL2569236 | 1.00 | ELANE (0.45) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL16256989 | 0.94 | ELANE (0.49) | ELANECA1CA2POLBLMNA | |
| SCHEMBL29510702 | 0.94 | ELANE (0.49) | ELANECA1CA2POLBLMNA | |
| SCHEMBL8481733 | 0.92 | GAA (0.46) | ELANECA1CA2POLBKMT2A | |
| SCHEMBL7301497 | 0.92 | GAA (0.46) | ELANECA1CA2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014127747-A1 | DPP-IV-INHIBITING COMPOUNDS AND INTERMEDIATES THEREOF | 成都先导药物开发有限公司 (CN) | 2014-08-28 | — | — | WO | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | ELANE 1037/4885CA1 4107/4885CA2 3810/4885 |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | ELANE 191/4885CA1 4413/4885CA2 3488/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | ELANE 190/4885CA1 4288/4885CA2 3213/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | ELANE 197/4885CA1 4541/4885CA2 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.